Attention-deficit hyperactivity disorder (ADHD) is a condition that has a worldwide prevalence ranging from 3% to 8% in the paediatric population.
INTRODUCTION
peractivity. 7 SHR showed differences in molecules regulating synaptic plasticity and in axon and dendrite development compared to WKY. 8 Decreased expression in synaptotagmin, Munc18, synaptosomal-associated protein, Brain-derived neurotrophic factor and increased expression in the dopamine transporter, syntaxin and synaptophysin were reported in SHR compared to WKY. 9 Psychostimulants such as methylphenidate (MPH), are the mainstay of treatment for ADHD. Previous reports show a delay in regional cortical maturation in ADHD, most prominently in prefrontal regions important for the control of attention and motor planning. 10 Neuroanatomical analysis has also revealed delayed maturation in the cortical regions of ADHD patients. 10 Moreover, the prefrontal cortex is posited to play a prominent role in the therapeutic actions of lowdose stimulants. 11 Another study showed increased glucose uptake in the cerebral cortex, basal hyperactivity, and paradoxical decreased locomotion after chronic methylphenidate injection. 12 Therefore, we hypothesized that MPH may mediate therapeutic effects by restoring the molecular differences between WKY in the prefrontal cortex of SHR.
Cyclin dependent kinase 5 (Cdk5) is a serine/threonine kinase, which requires association with p35 for activation. 13 The ratio of p25/p35 is also important in the regulation of Cdk5. 14 The BGEE gene expression (https://bgee.org) database 15 reports that Cdk5 is expressed in the frontal cortex and dorsolateral prefrontal cortex of human brain, brain areas which showed early maturation in ADHD children compared to children who develop normally. 10, 16 In comparison, Cdk5 was not detected in the primary motor cortex. 15 In one study, p35 deficient mice which have non-functional Cdk5 as the consequence of p35 deficiency, were reported to exhibit hyperactivity, 17 a core feature of ADHD. Dysfunction of Cdk5 during development may affect the dopamine pathway, a pathway also strongly implicated in ADHD etiology. 12 It has also been suggested that Cdk5 mediates these actions through auxiliary control of synaptic vesicle release and upstream synthesis of dopamine in the forebrain. 18 Studies have linked Cdk5 to Tropomyosin receptor kinase (TrkB) and Brain-derived neurotrophic factor-stimulated dendrite growth, 19 moesin-controlled neuronal spine formation, 20 and collapsin response mediator protein-2 (CRMP-2) regulated specification of neuronal axon/dendrite fate. 21, 22 Cdk5 also forms a complex with Munc18 (otherwise known as syntaxin binding protein) 23 to regulate soluble N-ethylmaleimidesensitive factor attachment protein receptor (SNARE) complex, which includes syntaxin 1A (STX1A) and synaptosomalassociated protein 25 (SNAP25). 24 In this study, we hypothesized that MPH can eliminate the molecular differences in WKY and SHR. Cdk5 and molecular substrates of Cdk5, which play a pivotal role in synaptic plasticity and in axon and dendrite, were examined in the modulation of therapeutic effects of MPH in SHRs (a model for ADHD) ( Figure 1A ).
METHODS

Animal treatment
Protocols for animal use were reviewed and approved by the Institutional Animal Care and Use Committee at the Sahmyook University (No. SYUIACUC 2015-005, SYUIACUC 2016-002) and were in accordance with National Institute of Health guidelines. Male 4 weeks old, SHR and WKY (Charles River, Japan) were used. Vehicle-treated animals were injected intraperitoneally with distilled water for 7 days, and MPH-treated animals were injected intraperitoneally with MPH (2 mg/kg, i.p.) for 7 consecutive days during the adolescent period (post-natal days 29-35). The dosage was decided based on a previous study which showed that 2.5 mg/ kg MPH improves attentional set-shifting at in SHRs. 25 We compared between vehicle-treated SHRs, vehicle-treated WKYs and MPH-treated SHRs. The animals were given access to food and water ad libitum and housed in a 12 hour light/dark cycle. The controls were given same volume of vehicle (distilled water) injections intraperitoneally as the MPH treated groups.
Western blotting analysis
Animals were sacrificed at 24 h after last injection of MPH, and the rat brain was dissected on ice. The prefrontal cortex, striatum and hippocampus tissue were removed and homogenized in lysate buffer; 50 mM Tris-base (pH 7.5), 150 mM NaCl, 2 mM EDTA, 1% glycerol, 10 mM NaF, 10 mM Na pyrophosphate, 1% NP-40, and protease inhibitors cocktail. Protein concentration was determined by Bradford (Bio-Rad, Hercules, CA, USA) method. Thirty micrograms of cell lysates were electrophoresed in SDS-polyacrylamide gels (SDS-PAGE) and transferred to nitrocellulose membranes, which were then incubated with anti-SNAP25 (1:1,000) (Santa Cruz Biotechnology, Dallas, TX, USA), anti-TrkB (1:1,000), antiCdk5 (1:1,000), anti-CRMP2 (1:1,000), anti-STX1A (1:1,000), anti-β-actin (1:1,000), anti-p35/p25 (1:1,000), anti-Munc18 (1:1,000), and anti-Moesin (1:2,000) 26 antibodies for 16 h at 4°C. After washing with TBS-T (0.05%), the blots were incubated with horseradish peroxidase-conjugated anti-rabbit (1:3,000) or anti-mouse IgG (1:3,000) (Pierce Biotechnology, Rockford, IL, USA), and the bands were visualized using the ECL system (Pierce Biotechnology, Rockford). Band images were obtained by using a Molecular Imager ChemiDoc XRS+ (Bio-Rad, Hercules) and band intensity was analyzed using Image Lab TM software version 2.0.1 (Bio-Rad, Hercules).
Statistical analysis
All statistical analyses were conducted with SPSS (version 19, Somers, NY, USA). The intensity of each band was normalized to that of β-actin (data not shown) and shown as mean±standard deviation (error bar). Group comparison was made using analysis of variance test (ANOVA) and post-hoc comparison was done using LSD method. The p-value of 0.05 or less was considered statistically significant.
RESULTS
Cdk5 proteins and p25/p35 ratio
Cdk5 levels ( Figure 1B ) in the prefrontal cortex of vehicletreated SHR (69.9±9.1%) were significantly decreased compared to Cdk5 levels in vehicle-treated WKY (127.7±26.3%, p<0.01). After 7 days of treatment with 2 mg/kg MPH, Cdk5 levels in the prefrontal cortex of MPH-treated SHR (127.6± 10.4%) were increased compared to Cdk5 levels in vehicletreated SHR (69.9±9.1%, p<0.01) and to the levels expressed in WKYs. In the hippocampus, Cdk5 levels in vehicle-treated SHR (82.1±13.1%) were increased compared to Cdk5 levels in vehicle-treated WKY (112.4±16.9%, p<0.05) and decreased compared to Cdk5 levels in MPH-treated SHR (35.0±5.1%, p<0.01). In the prefrontal cortex, the ratio of p25/p35 was significantly decreased in vehicle-treated SHR (0.63±0.18%) compared to vehicle-treated WKY (1.01±0.05%, p<0.01), and p25/p35 was significantly decreased in MPH-treated SHR (0.20±0.07%) compared to vehicle-treated SHR (0.63±0.18%, p<0.01) ( Figure 1C ). We observed that in striatum, p25/p35 was significantly decreased in vehicle-treated SHR (0.45± 0.22%) compared to vehicle-treated WKY (1.38±0.10%, p< 0.01), but there was no significant difference in p25/p35 in MPH-treated SHR (0.19±0.03%) compared to vehicle-treated SHR (0.45±0.22%). In the hippocampus, there was no difference in the ratio of p25/p35 between groups (vehicletreated WKY 1.25±0.13%, vehicle-treated SHR 1.18±0.73%, MPH-treated SHR 0.25±0.12%).
TrkB, Moesin and CRMP-2 proteins
In the prefrontal cortex, TrkB levels ( Figure 1D ) in vehicletreated SHRs (67.5±25.6%) were significantly decreased compared to TrkB levels in vehicle-treated WKY (107.4±12.9%, p<0.05). After MPH treatment, the TrkB levels (MPH-treated SHR 105.2±7.2%) in the prefrontal cortex were increased compared to TrkB levels in vehicle-treated SHR (67.5±25.6%, p<0.05). TrkB (MPH-treated SHR 318.4±106.3% compared to vehicle-treated SHR 86.3±39.0%, p<0.01) and Moesin ( Figure 1E ) (MPH-treated SHR 152.4±42.8% compared to A vehicle-treated SHR 17.6±9.1%, p<0.05) levels in SHRs were significantly increased in the striatum after MPH treatment. We observed that TrkB (vehicle-treated SHR 82.1±13.1% compared to vehicle-treated WKY 112.4±16.9%, p<0.05), and Moesin (vehicle-treated SHR 27.8±4.1% compared to vehicle-treated WKY 100.0±17.0%, p<0.01) levels were also decreased in the hippocampus in vehicle-treated SHRs compared to vehicle-treated WKYs, and the MPH treatment did not increase the expression levels of these proteins in MPHtreated SHRs compared to vehicle-treated SHRs. CRMP-2 ( Figure 1F ) was also significantly decreased in the prefrontal cortex of vehicle-treated SHRs (61.1±2.6%) compared to vehicle-treated WKYs (98.0±15.4%, p<0.01). However, the increase in CRMP-2 after MPH treatment was statistically insignificant. Figure 1G ) (vehicle-treated SHR 55.3±7.0% compared to 101.0±6.0% of vehicle-treated WKY, p<0.05), SNAP25 ( Figure 1H ) (vehicle-treated SHR 27.5±8.1% compared to 106.8±24.8% of vehicle-treated WKY, p<0.05), and Munc18 ( Figure 1I ), (vehicle-treated SHR 83.4±8.1% compared to 110.4±11.2% of vehicle-treated WKY, p<0.05) levels were significantly decreased in the prefrontal cortex of vehicletreated SHR compared to the levels of these proteins in vehicle-treated WKY. After MPH treatment, the STX1A (MPHtreated SHR 76.5±15.0% compared to 55.3±7.0% of vehicletreated SHRs, p<0.01) and SNAP25 (MPH-treated SHR 212.1±54.2% compared to 27.5±8.1% of vehicle-treated SHRs, p<0.01) levels in the prefrontal cortex of MPH-treated SHR were increased compared to the levels of these proteins in WKYs. SNAP25 levels were significantly increased in the striatum (vehicle-treated SHR 227.2±20.0% compared to 93.5±13.0% of vehicle-treated WKY, p<0.01) and the hippocampus (vehicle-treated SHR 461.7±50.0% compared to 137.0±54.8% of vehicle-treated WKY, p<0.01) in vehicletreated SHR compared to SNAP25 levels in vehicle-treated WKY. MPH treatment significantly increased the expression levels of SNAP25 in the striatum (MPH-treated SHR 293.4 ±25.8% compared to 227.2±20.0% of vehicle-treated SHRs, p<0.01) and the hippocampus (MPH-treated SHR 732.0± 102.2% compared to 461.7±50.0% of vehicle-treated SHRs, p<0.01). STX1A (vehicle-treated SHR 17.9±8.8% compared to 100.2±38.4% of vehicle-treated WKY, p<0.05), and Munc18 (vehicle-treated SHR 68.7±9.8% compared to 90.6 ±9.3% of vehicle-treated WKY, p<0.05) were also decreased in the hippocampus of vehicle-treated SHRs compared to vehicle-treated WKY, and MPH treatment did not increase the expression levels of these proteins in MPH-treated SHR compared to those of vehicle-treated SHRs.
STX1A, SNAP25, and Munc18 proteins
STX1A (
DISCUSSION
We investigated the role of Cdk5 and the substrates of Cdk5 in mediating the therapeutic effects of MPH. We observed that decreased expression of Cdk5, TrkB, STX1A, and SNAP25, were restored to the levels in WKYs after MPH treatment in the prefrontal cortex of SHRs. These results suggest that MPH restores Cdk5 expression in SHRs to the expression level in WKYs.
In this study, the relative p25/p35 ratio was decreased after MPH treatment due to a decrease in p25, rather than an increase in p35. The result suggests that MPH may regulate Cdk5 by decreasing the relative p25/p35 ratio. Previous studies have shown that Cdk5/p25 association causes aberrant hyperphosphorylation of substrates of Cdk5, 27 and that reducing Cdk5 activity through knockout of p35 induces behavioral hyperactivity in mice. 12 In a post-mortem study, genetic variation of SNAP25 confers risk for ADHD and reduces the expression of the SNAP25 transcript in a region of the brain that is critical for the regulation of attention and inhibition. 28 Coloboma mice, which are mice with a 50% reduction in SNAP25 protein levels, manifest locomotor hyperactivity. 29, 30 The hyperactivity manifested by Coloboma mice is ameliorated by low-dose amphetamine but not by MPH. 29, 30 In our study similar results were observed. MPH increased SNAP25 protein levels in SHRs to WKY levels, which is not possible for mice with deletions in the SNAP25 gene. The paradoxical response to MPH in Coloboma mice, along with our observations, suggest that MPH may exert its therapeutic effect through an increase in the level of SNAP25 protein in the prefrontal cortex.
TrkB is a protein with major function in neurite growth, which is also regulated by Cdk5. TrkB-signaling gene knockout 31 showed impaired hippocampal-dependent learning deficits in mice, similar to the learning impairment reported in ADHD. STX1A directly interacts with dopamine and regulates dopamine-mediated amphetamine-induced efflux. 32 Therefore, altered STX1A function may modulate dopamine systems, contributing to ADHD symptoms. 33 In this study, the expression of TrkB was decreased in vehicle-treated SHRs compared to vehicle-treated WKYs. Moreover, STX1A which was decreased in vehicle-treated SHRs compared to vehicletreated WKYs, were also restored to the levels in WKYs after MPH treatment. These results suggest that synaptic vesicle mobilization and neurite outgrowth pathways may play an important role in the therapeutic effects of MPH.
The results of this study, showed that Cdk5, TrkB, STX1A, and SNAP25 were involved in the modulation of MPH effects in the prefrontal cortex of SHRs, suggesting that synaptic vesicle mobilization and neurite outgrowth pathways may play an important role in ADHD pathophysiology and treatment.
